Program
Vaccines, Combined
Also written as “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, “LBVD (Hexavalent vaccine)” and “DPT-IPV-Hib (Combined Vaccine)”.
Its studies are mostly in Hepatitis B · Diphtheria · Haemophilus Infections · Tetanus, led by 3 companies.
Drug pageVaccines, Combined: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharma | 20 open or running | phase 3since Jun 13, 2017 | Jun 13, 2017 | none ahead |
| LG Chemits history only | 10 open or running | phase 3since Jul 11, 2022 | Jul 11, 2022 | none ahead |
| Serum Institute of India Pvt.its history only | 11 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | Oct 2027phase 2 · NCT07855172 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tanabe Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2017First study: phase 3 study in Haemophilus InfectionsFirst studyNCT03188692 · 33 enrolled · Japan
- Mar 24, 2019Phase 3 study in TetanusNCT03891758 · 267 enrolled · Japan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 2 Tanabe Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03891758Tetanus · Japan | 3 | Completed | Sep 18, 2019 | 267 |
| NCT03188692Haemophilus Infections · Japan | 3 | Completed | Nov 2, 2017 | 33 |
How it is read
Names in the registry
- “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, 1 entry
- “LBVD (Hexavalent vaccine)”, 1 entry
- “DPT-IPV-Hib (Combined Vaccine)”, 1 entry
- “DPT-IPV-Hib”, 1 entry
Codes read as this program: BK1310.
Conditions, from the studies’ own filings
- Hepatitis B, 1 study
- Diphtheria, 1 study
- Haemophilus Infections, 1 study
- Tetanus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.